Published in Vaccine Weekly, November 24th, 1997
The use of autologous cell cancer vaccines in clinical practice is limited by the invasive nature of harvesting cells, as well as the difficulty and expense of culturing and processing these cells. Justina Kayaga, representing colleagues from the St. George's Hospital Medical School, the Kings College School of Medicine and Dentistry, and the Royal Marsden Hospital, United Kingdom, presented results from animal studies using an alternative allogenic melanoma cell vaccine at the 3rd European Conference on Gene Therapy of Cancer, held...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.